Revance Therapeutics (RVNC) Misses Q1 EPS by 3c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.03 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $24.01 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• Beike (BEKE) PT Raised to $23 at Morgan Stanley